
Draig Therapeutics Launches with $140 Million (£107 Million) Total Investment to Advance its Portfolio of Next-Generation Therapies for Major Neuropsychiatric Disorders
SV Health Investors’ Dementia Discovery Fund Announces $269m Final Close of DDF-2

Packaging Compliance Labs Completes Acquisition of Quest Engineering Solutions, Expands Testing Capabilities and East Coast Presence

SUN Behavioral Health Acquires Seaside’s Community Agencies, Expanding Access to Community-Based Mental Health Services Across the Southeast

Centauri Health Solutions Acquires MedAllies, Broadens Health Data Network to Support Mission Critical Use Cases
British Patient Capital announces £25m commitment to SV Health Investors’ Dementia Discovery Fund 2

Ria Health Raises Growth Capital to Accelerate Access to Patient-Driven AUD Treatment

2024 SV Therapeutics Impact & ESG Report
Read More

Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas

Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System

SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise

Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –

Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix

Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure

Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
Read More

SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion

Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation

QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics

SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner

Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership

Merck to Acquire Caraway Therapeutics, Inc.

EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases

SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
- 10 May 2021Therini Bio Secures $17 Million Investment to Advance Fibrin Therapeutic Candidates Towards the Clinic
- 5 May 2021SV NewsThe Dementia Discovery Fund Appoints Luca Santarelli, M.D., a Proven Neuroscience Leader, as the New Chair of its Scientific Advisory Board
- 4 May 2021Cumulus Neuroscience Announces £6 million Funding Round Led by the Dementia Discovery Fund and joined by LifeArc and UK Future Fund
- 15 April 2021Alchemab raises £60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics
- 7 April 2021SV NewsThe Dementia Discovery Fund Significantly Enhances its Neuroscience R&D Expertise to Support its Portfolio
- 17 March 2021Amathus Therapeutics signs strategic collaboration with Merck to Develop Treatments for Neurodegenerative Diseases
- 16 March 2021Alchemab and Medicines Discovery Catapult to develop landmark novel antibody therapy for Huntington’s disease
- 2 February 2021QurAlis Continues to Expand Leadership Team with Two Key Hires
- 6 January 2021Ribometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics
- 18 November 2020Caraway Therapeutics Receives Research Grant from The Michael J. Fox Foundation to Further Investigate the Function of the Lysosomal Ion Channel TMEM175 and Gene Variants Linked to Parkinson’s Disease
- 16 November 2020Cerevance’s CVN058 Achieves Primary Endpoint in Phase 1b Schizophrenia Cognition Study
- 12 November 2020Nitrome Biosciences Announces Formation of Scientific Advisory Board and Appointment of Former AbbVie Executive James Summers, Ph.D. to SAB Chairperson